Medicago, PATH deal

The not-for-profit awarded Medicago US$946,000 in funding for a research collaboration to co-develop a seasonal or pandemic influenza vaccine for the developing world based on Medicago's virus-like particles (VLP) vaccine technology. Further terms were not disclosed. ...